# The treatment, Lormalzi (donanemab) is among the first- of- its-kind to target amyloid plaques in the brain.

*biotech · news · 2026-05-13 · Times of India*

## Key points

- Eli Lilly has launched its Alzheimer's drug Lormalzi (donanemab) in India.
- Lormalzi targets amyloid plaques in the brain, shifting treatment beyond just cognitive symptom relief.
- The drug costs nearly Rs 92,000 per 350 mg vial and is administered intravenously every four weeks.
- Lormalzi received marketing authorisation for Alzheimer’s with mild cognitive impairment or early dementia.
- A Phase IV trial will be held in India to gather local safety and efficacy data.

**Companies:** Eli Lilly, Lupin, Cipla
**Countries:** United States, India

[Read the full story on Times of India](https://timesofindia.indiatimes.com/business/india-business/lilly-expands-specialty-portfolio-in-india/articleshow/131071530.cms)

---

Canonical: https://newsio.io/n/724d324c-7a85-4670-98b6-64548521009e/the-treatment-lormalzi-donanemab-is-among-the-first-of-its-kind-to-target-amyloi
Summarized by Newsio from Times of India. https://newsio.io/how-it-works